ARTICLE | Top Story
FDA approves Ampyra
January 23, 2010 1:20 AM UTC
Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $2.50 (10%) to $28.12 on Friday after FDA approved an NDA for Ampyra dalfampridine (formerly Fampridine-SR) to improve walking ability in patients with mu...